Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totaling 139 shares, a growth of 256.4% from the August 15th total of 39 shares. Based on an average daily volume of 18 shares, the days-to-cover ratio is currently 7.7 days. Approximately 0.0% of the company’s shares are short sold.
Basilea Pharmaceutica Stock Performance
Shares of OTCMKTS:BPMUF opened at $77.40 on Monday. The business has a fifty day simple moving average of $67.65 and a 200-day simple moving average of $67.48. Basilea Pharmaceutica has a 52 week low of $59.29 and a 52 week high of $77.40. The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica Ltd. is a Swiss biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology applications. The company was established in 2000 as a spin-off from Roche and is headquartered in Basel, Switzerland.
Basilea’s commercial portfolio includes Cresemba (isavuconazole), an antifungal used to treat invasive aspergillosis and invasive mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- Why Bitcoin ETFs May Be Worth Another Look as Inflows Rebound
- 3 Small-Cap Biotechs With Binary Catalysts on the Calendar
- Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
- As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
